Zanidatamab Expands First-Line HER2-Positive GI Care
FDA authorized two zanidatamab-based first-line strategies with chemotherapy, with or without tislelizumab, for HER2-positive upper gastrointestinal adenocarcinoma, emphasizing accurate testing and individualized treatment selection today.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.